Generic & Biosimilar Opportunities with Respect to Multi-Therapy Drugs Reviewed in New Report Published by MarketPublishers.com

01 Nov 2011 • by Natalie Aster
Generic & Biosimilar Opportunities with Respect to Multi-Therapy Drugs Reviewed in New Report Published by MarketPublishers.com

LONDON – As used here, the term multi-therapy drug refers to any drug that has either been approved for, or is in clinical development for, more than one distinct indication during its lifecycle.  Multiple indications may be within an established therapy area, such as cancer, immunology or the nervous system, or they may be from different areas.  Rituxan/MabThera (rituximab), for example, has been approved for both oncological and immunological conditions.  Other drugs may be useful in several cancer indications or across a range of immunological or psychological conditions.

Having established their usefulness in a number of indications, many of these drugs benefit from a wide patient pool and annual sales are counted in billions of dollars.  The total sales of the multi-therapy drugs exceeded USD 70 billion last year.

New report “Multi-therapy Drugs: Opportunities for Generics & Biosimilars” developed by Espicom has been recently published by Market Publishers Ltd.

Report Details:

Title: Multi-therapy Drugs: Opportunities for Generics & Biosimilars
Published: October, 2011
Pages: 108
Price: US$ 1,740

The report aims to establish generic and biosimilar opportunities with respect to high-value multi-therapy drugs.

Report Contents:

FOREWORD

EXECUTIVE SUMMARY

OVERVIEW
Lifecycle Development and New Indications
  Realising Additional Sales Potential
    Rituximab: Multiple Indications from Oncology to Immunology
    Sildenafil: One Active Ingredient, Two Distinctly Branded Indications
Generic and Biosimilar Opportunities
    Biosimilar Approval for Multiple Indications: Extrapolation or Additional Trials?
    US Patent Expiries

PRODUCT ANALYSIS

ANTI-METABOLITES
  Alimta (pemetrexed)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Xeloda (capecitabine)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
      Colorectal Cancer
      Breast Cancer
      Gastric Cancer
    Patents
    Generic Company Activity
    Market Outlook

MONOCLONAL ANTIBODIES
  Rituxan/MabThera (rituximab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Biosimilar Activity
    Market Outlook
  Herceptin (trastuzumab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
      Breast Cancer
      Gastric Cancer
    Patents
    Biosimilar Activity
    Market Outlook
  Erbitux (cetuximab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Biosimilar Activity
    Market Outlook
  Avastin (bevacizumab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Biosimilar Potential
    Market Outlook

PROTEIN KINASE INHIBITORS
  Glivec (imatinib)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Tarceva (erlotinib)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Sutent (sunitinib)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Nexavar (sorafenib)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook

OTHER ANTINEOPLASTIC AGENTS
  Velcade (bortezomib)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook

IMMUNOSUPPRESSANTS
  Enbrel (etanercept)
    Mode of Action
    Approvals
    Competition within the Marketplace
    Patents
    Biosimilar Activity
      Merck & Co
      Avesthagen
      Protalix BioTherapeutics
      Simcere
    Market Outlook
  Remicade (infliximab)
    Mode of Action
    Approvals
    Competition within the Marketplace
    Patents
    Biosimilar Activity
    Market Outlook
  Humira (adalimumab)
    Mode of Action
    Approvals
    Competition within the Marketplace
    Patents
    Biosimilar Activity
    Market Outlook
  Cimzia (certolizumab pegol)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Biosimilar Potential
    Market Outlook
  Actemra (tocilizumab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Biosimilar Potential
    Market Outlook
  Afinitor/Zortress (everolimus)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Renal Cell Carcinoma
    Breast Cancer
    Patents
    Generic Company Activity
    Market Outlook
  Tysabri (natalizumab)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Market Outlook

NERVOUS SYSTEM
  Lyrica (pregabalin)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Seroquel (quetiapine)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
      Seroquel XR
      Seroquel IR
    Market Outlook
  Abilify (aripiprazole)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook
  Cymbalta (duloxetine)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook

OTHER
  Viagra & Revatio (sildenafil)
    Mode of Action
    Approvals
    Lifecycle Development
    Competition within the Marketplace
    Patents
    Generic Company Activity
    Market Outlook

SOURCES
Espicom Sources
Others

DIRECTORY
Regulators
Manufacturers

INDEX

LIST OF TABLES

LIST OF FIGURES

More new research reports by the publisher can be found at Espicom page.

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com